FDA warns of severe risks from misbranded GLP-1 weight-loss drugs
The FDA warned patients and providers about severe health risks from unapproved and compounded GLP-1 weight-loss drugs, including illegally marketed semaglutide and tirzepatide. Hims & Hers stock closed 3.85% lower Tuesday.